Followers of the specialist cancer drug discovery and development Company were rewarded for their patience at the end of May this year when its CHK1 inhibitor programme saw a candidate (CCT245737) enter the clinic, some nine years after its Company and its partners announced that its compounds showed activity in targeting Checkpoint Kinase 1. The journey between the first in man dosage and license agreement has been much quicker with an agreement announced this week with NASDAQ listed ProNAi
28 Sep 2016
Chk1 collaboration secures license agreement. Headline value $319.5m
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Chk1 collaboration secures license agreement. Headline value $319.5m
Sareum Holdings plc (SAR:LON) | 11.0 -0.4 (-24.1%) | Mkt Cap: 7.89m
- Published:
28 Sep 2016 -
Author:
Derren Nathan -
Pages:
7
Followers of the specialist cancer drug discovery and development Company were rewarded for their patience at the end of May this year when its CHK1 inhibitor programme saw a candidate (CCT245737) enter the clinic, some nine years after its Company and its partners announced that its compounds showed activity in targeting Checkpoint Kinase 1. The journey between the first in man dosage and license agreement has been much quicker with an agreement announced this week with NASDAQ listed ProNAi